Exhibit 99.1
 |
ADMA BioCenters Receives FDA Approval for its Sixth Plasma Collection Center, Located in Myrtle Beach, SC
FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth
Company is on-track to have all 10 plasma collection centers FDA-approved by year-end 2023
RAMSEY, N.J., BOCA RATON, Fla. and Myrtle Beach, SC. – June
27, 2022 – ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S.
Food and Drug Administration (“FDA”) approval for its sixth ADMA BioCenters plasma collection facility located in Myrtle Beach, South Carolina. This plasma collection facility commenced operations and initiated source plasma collection in the fourth
quarter of 2021. With the approval announced today, this facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.
“The successful expansion of ADMA’s plasma collection network supports the Company’s goal of plasma supply self-sufficiency,
ongoing revenue growth objectives, and further supports the pathway towards profitability. The approval is a testament to the BioCenters team’s tireless commitment, and we thank the FDA for its efforts and expeditious review of the Myrtle Beach, SC
Biologics License Application (“BLA”), which came well in advance of ADMA’s anticipated approval date,” said Adam Grossman, President and Chief Executive Officer of ADMA.
“ADMA’s multi-year strategic initiative to establish plasma supply self-sufficiency is nearing a successful completion. The Company has ten plasma collection
centers under its corporate umbrella at various stages, six of which are now FDA-approved to collect normal source and RSV hyperimmune plasma. Importantly, the substantial capital investments required to support the BioCenters’ expansion have now
largely been made, and as a result, we expect to derive meaningful cost efficiencies from the business segment in the periods ahead. We anticipate the Company’s growing plasma supply position will enable ADMA to continue to expand its customer base
and grow revenues in the U.S. immunoglobulin market,” said Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager, ADMA BioCenters.
This new, state-of-the-art plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process,
free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the
plasma center expects to maintain a staff of 50 highly trained healthcare workers. This center is approved to use the state-of-the-art Haemonetics NexSys Persona® plasma collection system.
To learn more about the ADMA BioCenters donation process, and to schedule an
appointment, please visit: www.admabiocenters.com, or visit in person
at: 100 Legends Dr. Unit 1, Myrtle Beach, SC 29579, United States.
|
About ADMA BioCenters
ADMA BioCenters is an FDA-licensed facility specializing in the collection of human plasma used to make special medications for the treatment and
prevention of diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA
regulations and guidance and enforces cGMP (current good manufacturing practices) in all of its facilities. For more information about ADMA BioCenters, please visit www.admabiocenters.com.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived
biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived
biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous,
human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its
products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised
patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No.
3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
about ADMA Biologics, Inc. and its subsidiaries (collectively, “ADMA”, “we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or
achievements, and may contain such words as “anticipate,” “intend,” “target,” “plan,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar
meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations (including, but not limited to, revenue growth); expansion plans and the goal of operating ten or more FDA-approved
plasma collection centers by year-end 2023; our pathway to profitability; the Company’s plasma supply and ability to become plasma self-sufficient; the Company’s growing customer base and revenue as a result of its strong plasma supply position; and
the expected staff count at the Myrtle Beach, SC facility. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that
there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any
forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events,
to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our
most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
|
COMPANY CONTACT:
Skyler Bloom
Senior Director, Corporate Strategy and Business Development | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com